News on "Compare Drugs"
07/29/2010
Dispensary Of Hope Welcomes Sanofi-Aventis U.S. As Latest Participant In The Continued Access Program
The Dispensary of Hope is pleased to announce that sanofi-aventis U.S., the U.S. affiliate of sanofi-aventis, a leading global pharmaceutical company, has become the latest pharmaceutical company to participate in the Dispensary's Continued Access Program, which provides uninsured patients with access to medicines that they otherwise couldn't afford...
07/29/2010
Dispensary Of Hope Welcomes Sanofi-Aventis U.S. As Latest Participant In The Continued Access Program
The Dispensary of Hope is pleased to announce that sanofi-aventis U.S., the U.S. affiliate of sanofi-aventis, a leading global pharmaceutical company, has become the latest pharmaceutical company to participate in the Dispensary's Continued Access Program, which provides uninsured patients with access to medicines that they otherwise couldn't afford...
07/29/2010
New Tool For Accessing Bioinformatics Resources
Developed by researchers at the UPM's Facultad de Informática, this tool can discover and automatically classify bioinformatics resources from the scientific literature. Bioinformatics resources have proliferated in the years since the end of the Human Genome Project, obliging researchers to spend a quite a lot of time browsing the web in search of these resources...
07/29/2010
New Tool For Accessing Bioinformatics Resources
Developed by researchers at the UPM's Facultad de Informática, this tool can discover and automatically classify bioinformatics resources from the scientific literature. Bioinformatics resources have proliferated in the years since the end of the Human Genome Project, obliging researchers to spend a quite a lot of time browsing the web in search of these resources...
07/29/2010
New England Journal Of Medicine Publishes Data From Pivotal Phase 3 PROVENGE IMPACT Study
Dendreon Corporation (Nasdaq: DNDN) announced the publication of data from the pivotal Phase 3 IMPACT study in the New England Journal of Medicine, showing that PROVENGE® (sipuleucel-T) demonstrated a statistically significant improvement in overall survival compared to control in men with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer (mCRPC)...
